Sigvotatug vedotin is under clinical development by Pfizer and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData, Phase III drugs for Non-Small Cell Lung Cancer have a 46% ...

Telisotuzumab vedotin is under clinical development by AbbVie and currently in Pre-Registration for Non-Small Cell Lung Cancer. According to GlobalData, Pre-Registration drugs for Non-Small Cell Lung ...

Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer (NSCLC) whose tumours overexpress c-Met. The c-Met protein ...

This study demonstrates the utility of Nectin-4-targeted positron emission tomography (PET) imaging using [68Ga]AJ647 as a non-invasive tool for real-time assessment of target engagement in enfortumab ...